Quick answer: CJC-1295 and Ipamorelin are both studied for growth-hormone (GH) release, but through two different receptors. CJC-1295 is a GHRH analog that activates the pituitary GHRH receptor. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. Because they act on separate pathways, researchers study them together — one provides the “release signal,” the other amplifies the pulse. Sold for research use only.
The core distinction
The simplest framing: CJC-1295 tells the pituitary to make GH (GHRH pathway); Ipamorelin tells it to release a pulse (ghrelin pathway). Activating one receptor produces a modest GH pulse; activating both at once is studied for a markedly larger, synergistic response than either alone.
Side-by-side
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog (growth-hormone-releasing hormone) | GHRP / selective ghrelin-receptor agonist |
| Receptor | Pituitary GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Studied mechanism | Sustained GHRH-type signaling; raises baseline GH/IGF-1 tone | Selective GH-pulse release with minimal cortisol/prolactin effect |
| DAC vs no-DAC | DAC version has a multi-day half-life (sustained); no-DAC is short-acting | Single short-acting form |
| Research framing | “Signal / baseline elevation” | “Pulse / selective release” |
Mechanisms in more detail
CJC-1295 is a synthetic GHRH analog that binds the pituitary GHRH receptor with high affinity to stimulate GH synthesis and release. The DAC (Drug Affinity Complex) version binds serum albumin, extending its half-life to several days; in published clinical research, CJC-1295 with DAC produced sustained, dose-dependent increases in plasma GH and IGF-1 from a single administration. The no-DAC version (“Mod GRF 1-29”) is short-acting, giving researchers tighter control over pulse timing.
Ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a) — the same pathway acylated ghrelin uses to trigger GH release from pituitary somatotrophs. Its defining research feature is selectivity: compared with earlier GHRPs, Ipamorelin releases GH with little effect on cortisol or prolactin, making it a cleaner tool for isolating GH-axis effects.
Why researchers study them together
The two occupy different receptors, so combining them is studied for a synergistic GH response: CJC-1295 raises the underlying GHRH signal while Ipamorelin drives a selective pulse on top of it. This dual-receptor design is why the pair is one of the most commonly referenced GH-research combinations. PTW offers both individually.
Frequently asked questions
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 is a GHRH analog acting on the pituitary GHRH receptor; Ipamorelin is a selective ghrelin-receptor agonist. They stimulate GH through two separate pathways.
Why are CJC-1295 and Ipamorelin studied together?
Because they hit different receptors, combining them is researched for a synergistic GH pulse larger than either produces alone.
What does “DAC” mean on CJC-1295?
DAC (Drug Affinity Complex) binds albumin to extend half-life to several days. The no-DAC form is short-acting and used when tighter timing control is needed.
What makes Ipamorelin “selective”?
It releases GH with minimal impact on cortisol and prolactin, unlike earlier GHRPs — useful for isolating GH-axis effects in research.
Are these for human use?
No. Portal to Wellness sells these strictly for laboratory and research use only. Nothing here is medical advice.
Primary-literature anchors
Cite primary sources: Teichman et al. (CJC-1295 with DAC, sustained GH/IGF-1, Journal of Clinical Endocrinology & Metabolism, 2006); Raun et al. (Ipamorelin, selective GH release with low cortisol/prolactin, European Journal of Endocrinology, 1998). Link via PubMed.
Related research & products
For research use only. Not for human or veterinary use, diagnosis, treatment, or prevention of any condition. Not evaluated by the FDA. Author: Charles Fowler. Last updated: May 2026.